Natalie K. Horvat

Natalie K. Horvat

Auto-generated profile, based on publicly available information

Natalie K. Horvat

Emory University 1 Department of Hematology and Medical Oncology Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2025 in Blood
Verified
Journal Article
Open access
MOMarques Oriana
Marques Oriana
NHNatalie K. Horvat
Natalie K. Horvat
LZLaura Zechner
Laura Zechner
SCSilvia Colucci
Silvia Colucci
RSRichard Sparla
Richard Sparla
MMMartina Ulrike Muckenthaler
Martina Ulrike Muckenthaler
Anemia of inflammation is a prevalent comorbidity in patients with chronic inflammatory disorders. Inflammation causes hypoferremia and iron-restricted erythropoiesis by limiting ferroportin (FPN)–mediated iron export from macrophages that recycle senescent erythrocytes. Macrophage cell surface expression of FPN is reduced by hepcidin-induced degradation and/or by repression of FPN (Slc40a1) transcription via cytokine and Toll-like receptor (TLR) stimulation. Although the mechanisms underlying hepcidin-mediated control of FPN have been extensively studied, those inhibiting Slc40a1 messenger RNA (mRNA) expression remain unknown. We applied targeted RNA interference and pharmacological screens in macrophages stimulated with the TLR2/6 ligand FSL1 and identified critical signaling regulators of Slc40a1 mRNA repression downstream of TLRs and NF-κB signaling. Interestingly, the NF-κB regulatory hub is equally relevant for Slc40a1 mRNA repression driven by the TLR4 ligand lipopolysaccharide, the cytokine tumor necrosis factor β/lymphotoxin-alpha (LTA), and heat-killed bacteria. Mechanistically, macrophage stimulation with heat-killed Staphylococcus aureus recruits the histone deacetylases (HDACs) HDAC1 and HDAC3 to the antioxidant response element (ARE) located in the Slc40a1 promoter. Accordingly, pretreatment with a pan-HDAC inhibitor abrogates Slc40a1 mRNA repression in response to inflammatory cues, suggesting that HDACs act downstream of NF-κB to repress Slc40a1 transcription. Consistently, recruitment of HDAC1 and HDAC3 to the Slc40a1 ARE after stimulation with heat-killed S aureus is dependent on NF-κB signaling. These results support a model in which the ARE integrates the transcriptional responses of Slc40a1 triggered by signals from redox, metabolic, and inflammatory pathways. This work identifies the long-sought mechanism of Slc40a1 transcriptional downregulation upon inflammation, paving the way for therapeutic interventions at this critical juncture.

Verified
Journal Article
Open access
PDF file
CMChristina Mertens
Christina Mertens
MOMarques Oriana
Marques Oriana
NHNatalie K. Horvat
Natalie K. Horvat
Manuela SimonettiManuela Simonetti
Manuela Simonetti
MMMartina Ulrike Muckenthaler
Martina Ulrike Muckenthaler
MJMichaela Jung
Michaela Jung
Throughout life, macrophages are located in every tissue of the body, where their main roles are to phagocytose cellular debris and recycle aging red blood cells. In the tissue niche, they promote homeostasis through trophic, regulatory, and repair functions by responding to internal and external stimuli. This in turn polarizes macrophages into a broad spectrum of functional activation states, also reflected in their iron-regulated gene profile. The fast adaptation to the environment in which they are located helps to maintain tissue homeostasis under physiological conditions.

16 June 2021 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
TBTobias A. Bauer
Tobias A. Bauer
NHNatalie K. Horvat
Natalie K. Horvat
OMOriana Marques
Oriana Marques
SCSara Chocarro
Sara Chocarro
CMChristina Mertens
Christina Mertens
Matthias BarzMatthias Barz
Matthias Barz
Iron is an essential co‐factor for cellular processes. In the immune system, it can activate macrophages and represents a potential therapeutic for various diseases. To specifically deliver iron to macrophages, iron oxide nanoparticles are embedded in polymeric micelles of reactive polysarcosine‐block‐poly(S‐ethylsulfonyl‐l‐cysteine). Upon surface functionalization via dihydrolipoic acid, iron oxide cores act as crosslinker themselves and undergo chemoselective disulfide bond formation with the surrounding poly(S‐ethylsulfonyl‐l‐cysteine) block, yielding glutathione‐responsive core cross‐linked polymeric micelles (CCPMs). When applied to primary murine and human macrophages, these nanoparticles display preferential uptake, sustained intracellular iron release, and induce a strong inflammatory response. This response is also demonstrated in vivo when nanoparticles are intratracheally administered to wild‐type C57Bl/6N mice. Most importantly, the controlled release concept to deliver iron oxide in redox‐responsive CCPMs induces significantly stronger macrophage activation than any other iron source at identical iron levels (e.g., Feraheme), directing to a new class of immune therapeutics.

8 January 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
NHNatalie K. Horvat
Natalie K. Horvat
IKIsaac Karpovsky
Isaac Karpovsky
MPMaggie Phillips
Maggie Phillips
MWMegan M. Wyatt
Megan M. Wyatt
MHMargaret A. Hall
Margaret A. Hall
GLGregory B. Lesinski
Gregory B. Lesinski
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor. Prognosis is poor and survival is low in patients diagnosed with this disease, with a survival rate of ~12% at 5 years. Immunotherapy, including adoptive T cell transfer therapy, has not impacted the outcomes in patients with PDAC, due in part to the hostile tumor microenvironment (TME) which limits T cell trafficking and persistence. We posit that murine models serve as useful tools to study the fate of T cell therapy. Currently, genetically engineered mouse models (GEMMs) for PDAC are considered a “gold-standard” as they recapitulate many aspects of human disease. However, these models have limitations, including marked tumor variability across individual mice and the cost of colony maintenance. Methods: Using flow cytometry and immunohistochemistry, we characterized the immunological features and trafficking patterns of adoptively transferred T cells in orthotopic PDAC (C57BL/6) models using two mouse cell lines, KPC-Luc and MT-5, isolated from C57BL/6 KPC-GEMM (KrasLSL-G12D/+p53−/− and KrasLSL-G12D/+p53LSL-R172H/+, respectively). Results: The MT-5 orthotopic model best recapitulates the cellular and stromal features of the TME in the PDAC GEMM. In contrast, far more host immune cells infiltrate the KPC-Luc tumors, which have less stroma, although CD4+ and CD8+ T cells were similarly detected in the MT-5 tumors compared with KPC-GEMM in mice. Interestingly, we found that chimeric antigen receptor (CAR) T cells redirected to recognize mesothelin on these tumors that signal via CD3ζ and 41BB (Meso-41BBζ-CAR T cells) infiltrated the tumors of mice bearing stroma-devoid KPC-Luc orthotopic tumors, but not MT-5 tumors. Conclusions: Our data establish for the first time a reproducible and realistic clinical system useful for modeling stroma-rich and stroma-devoid PDAC tumors. These models shall serve an indepth study of how to overcome barriers that limit antitumor activity of adoptively transferred T cells.

1 December 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NHNatalie K. Horvat
Natalie K. Horvat
GLGregory B. Lesinski
Gregory B. Lesinski
Myeloid-derived suppressor cells (MDSCs) hinder antitumor immunity in multiple cancer types. While brequinar (BRQ), an inhibitor of dihydroorotate dehydrogenase, shows cytotoxicity in hematological malignancy, it has not yet been adapted to attenuate MDSCs by augmenting bone marrow progenitors in breast cancer. In this issue of the JCI, Colligan et al. demonstrate that BRQ restored terminal differentiation of MDSCs. Using in vivo models of immunotherapy-resistant breast cancer, the authors uncovered a mechanism by which BRQ promoted myeloid cell differentiation by limiting their suppressive function and enhancing the efficacy of immune checkpoint blockade therapy. The findings offer insight into the biogenesis of MDSCs, provide an alternative avenue for cancers that remain unresponsive to conventional therapies, and may be extended to future translational studies in patients.

19 December 2025 in Cancer Research
Verified
Journal Article
Open access
EGEmily Greene
Emily Greene
NHNatalie K. Horvat
Natalie K. Horvat
DDDeon Bryant Doxie
Deon Bryant Doxie
VPVaunita Cohen Parihar
Vaunita Cohen Parihar
JKJayden Kim
Jayden Kim
GLGregory B. Lesinski
Gregory B. Lesinski
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor type with poor patient outcomes. Most patients present with metastatic disease, which generally has reduced immune infiltration compared with primary tumors. Further work to elucidate the specific cellular features of metastatic PDAC is needed to guide the development of future immunotherapy strategies. In this study, we investigated the hypothesis that PDAC tumors harbor distinct immunologic and stromal features depending on their anatomic site. Multiplex IHC, spatial analysis, and single-cell mass cytometry (CyTOF) uncovered dominant immune and stromal cell populations in tumors derived from 27 primary and 26 liver metastases. Metastatic liver tumors from patients with PDAC contained reduced T-cell infiltration, fibroblast populations, and collagen accumulation than primary lesions, whereas CD68+ cells, often coexpressing CCR2, were more abundant. Spatial analyses revealed distinct immune cell communities in primary and metastatic PDAC, in which cytokeratin 19 (CK19+) cells clustered differentially with αSMA+, CD3+, and CD68+ cells, depending on the tumor site. When comparing tumor-associated regions, the proportion of peritumoral CK19− cells remained consistent, but their composition varied by disease site. CD8+ T cells were significantly less frequent in metastatic tumors, whereas both CD4+ and CD8+ T cells present in primary tumors expressed more transcription factors associated with suppressive properties, including FoxP3 and RORγt. CyTOF revealed that T cells coexpressed multiple inhibitory checkpoint receptors, most notably LAG3 and PD-1. This report reveals that primary and metastatic tumors from patients with PDAC harbor vastly distinct immunologic and stromal features at the protein level. Significance: Protein level analysis reveals distinct immunological and stromal features between primary and metastatic pancreatic tumors, offering a rationale for immunotherapies that target macrophages and increase T-cell abundance in metastatic disease.